Cytology is the study of cells using a microscope.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces today that the Data and Safety Monitoring Board, an independent committee of experts which monitors safety data every six months during the study, met as scheduled on January 22nd. It recommended the RHEIA-VAC study proceed without any modifications.
Two leading medical organizations say that using a Human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing.
About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.
Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (LDCT) screening when their primary care provider is familiar with guideline recommendations for LDCT screening for lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Further underscoring its ongoing commitment to lung health, Covidien today unveiled a next-generation version of its superDimension™ Navigation System software. The updated software features a more intuitive interface that helps reduce time spent by physicians planning the procedure and enhances the visualization of the airways of the lung.
And the team of scientists, at the universities of Lyon and Saint-Etienne in France and Keele in the UK, found that the higher the aluminium, the lower sperm count.
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine, Philadelphia, Pennsylvania based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
Magnetic resonance spectroscopy can quantitatively analyze in vivo abnormalities of biochemical metabolism within brain tissue in a noninvasive and non-radioactive manner.
Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated.
Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield–affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's Afirma Gene Expression Classifier (GEC).
Health screens for cancer-causing infections like HPV can be challenging in developing countries, where residing in rural areas can result in limited access to health services.
Veracyte, Inc. today reported financial results for the first quarter ended March 31, 2014, and provided an update on recent business progress. For the first quarter of 2014, revenue was $7.5 million, an increase of 71%, compared to $4.4 million for the first quarter of 2013.
Roche announced today that the U.S. Food and Drug Administration approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas HPV Test the first and only HPV test in the United States approved for first-line primary screening.
Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.
BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.
Self-testing for Human Papillomavirus (HPV) - the virus that causes cervical cancer - is as effective at detecting cancer as a conventional smear test (cytology screening) even when scaled up to test large populations.
A new study from Karolinska Institutet in Sweden finds that testing for human papilloma virus (HPV) allows for longer time between screening tests when compared to cytology-based testing. The study is published in the scientific journal British Medical Journal (BMJ).
A collaboration between National Cancer Centre Singapore and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence. This new Centre facilitates the use of circulating tumour cells in clinical diagnostics, in order for new technologies to be applied by healthcare institutions.